Your browser is no longer supported. Please, upgrade your browser.
KLDO Kaleido Biosciences, Inc. daily Stock Chart
Kaleido Biosciences, Inc.
Index- P/E- EPS (ttm)-2.54 Insider Own0.10% Shs Outstand35.55M Perf Week10.12%
Market Cap262.74M Forward P/E- EPS next Y-1.98 Insider Trans- Shs Float32.34M Perf Month16.34%
Income-81.10M PEG- EPS next Q-0.24 Inst Own79.90% Short Float10.45% Perf Quarter16.34%
Sales0.70M P/S375.34 EPS this Y-59.90% Inst Trans-0.26% Short Ratio12.75 Perf Half Y-4.87%
Book/sh1.01 P/B7.54 EPS next Y10.40% ROA-104.90% Target Price11.60 Perf Year-7.41%
Cash/sh1.58 P/C4.82 EPS next 5Y- ROE-191.20% 52W Range2.82 - 11.89 Perf YTD51.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-35.91% Beta-
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin- 52W Low170.21% ATR0.47
Employees91 Current Ratio4.50 Sales Q/Q- Oper. Margin- RSI (14)51.67 Volatility6.49% 7.28%
OptionableNo Debt/Eq0.58 EPS Q/Q11.60% Profit Margin- Rel Volume0.12 Prev Close7.30
ShortableYes LT Debt/Eq0.55 Earnings- Payout- Avg Volume265.08K Price7.62
Recom2.40 SMA2011.57% SMA50-2.31% SMA20010.58% Volume32,893 Change4.38%
May-21-20Downgrade Morgan Stanley Overweight → Equal-Weight $8
Apr-23-19Initiated Chardan Capital Markets Buy $17.50
Mar-25-19Initiated Morgan Stanley Overweight $17
Mar-25-19Initiated JP Morgan Neutral $15
Mar-25-19Initiated Goldman Buy $20
Nov-24-20 03:00PM  
Nov-13-20 09:23AM  
Nov-02-20 07:35AM  
Oct-23-20 07:31AM  
Oct-07-20 07:30AM  
Oct-06-20 07:30AM  
Oct-02-20 12:09PM  
Oct-01-20 07:30AM  
Sep-29-20 07:30AM  
Sep-09-20 07:00AM  
Aug-27-20 07:00AM  
Aug-06-20 11:26AM  
Aug-05-20 08:00AM  
Aug-04-20 07:35AM  
Jul-23-20 07:00AM  
Jul-07-20 08:00AM  
Jun-16-20 04:45PM  
Jun-08-20 08:30AM  
Jun-07-20 08:54AM  
Jun-04-20 08:30AM  
Jun-01-20 09:30PM  
May-28-20 08:00AM  
May-27-20 03:14PM  
May-14-20 06:32AM  
May-12-20 08:30AM  
Apr-03-20 08:30AM  
Mar-31-20 11:30AM  
Mar-02-20 07:35AM  
Jan-09-20 08:00AM  
Jan-06-20 08:30AM  
Dec-22-19 01:52PM  
Dec-19-19 08:00AM  
Dec-12-19 08:00AM  
Nov-06-19 08:00AM  
Nov-05-19 01:36PM  
Oct-30-19 04:05PM  
Oct-25-19 04:44PM  
Oct-22-19 08:00AM  
Oct-03-19 08:00AM  
Sep-30-19 08:00AM  
Sep-27-19 07:56AM  
Sep-26-19 04:10PM  
Sep-09-19 07:30AM  
Sep-03-19 08:00AM  
Aug-29-19 08:00AM  
Aug-08-19 06:38AM  
Aug-01-19 07:30AM  
Jul-31-19 08:00AM  
Jul-22-19 08:00AM  
Jul-18-19 03:42PM  
Jul-15-19 08:00AM  
Jun-26-19 08:00AM  
Jun-03-19 08:00AM  
May-08-19 02:23PM  
May-02-19 07:30AM  
Apr-23-19 06:00AM  
Apr-12-19 07:30AM  
Apr-08-19 08:00AM  
Mar-27-19 08:15AM  
Mar-21-19 08:00AM  
Mar-08-19 08:30AM  
Mar-04-19 04:15PM  
Feb-28-19 11:30AM  
Feb-27-19 07:27PM  
Feb-24-19 02:34PM  
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company offers product candidates for the treatment of urea cycle disorders; hepatic encephalopathy; infections caused by multi-drug resistant bacteria; cardiometabolic and liver diseases; and immune oncology. It has a collaboration agreement with Gustave Roussy Cancer Center to develop microbiome metabolic therapies in immuno-oncology; a research collaboration with Washington University School of Medicine to explore the influence of microbiome metabolic therapies on microbial and host physiology and metabolism; and a research collaboration with Janssen to prevent childhood-onset of atopic, immune, and metabolic conditions. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flagship Ventures Fund IV Gene10% OwnerJun 04Buy7.502,000,00015,000,0002,910,972Jun 08 04:46 PM
MELAS KYRIAZI THEODirectorJun 04Buy7.5033,333249,99833,333Jun 05 04:06 PM